BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Status:
Terminated
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study was to determine whether treatment with BGJ398
demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or
hematologic malignancies to warrant further study.